NEURAMATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NEURAMATE (NEURAMATE).
NEURAMATE is a brand name for pentobarbital, a barbiturate that enhances GABA-A receptor activity by binding to the barbiturate binding site, increasing the duration of chloride ion channel opening, thereby producing CNS depression.
| Metabolism | Primarily hepatic via hydroxylation and conjugation; involves CYP450 enzymes (CYP2C9, CYP2C19); active metabolites; excreted renally. |
| Excretion | Primarily renal (90% unchanged) with 10% biliary/fecal. |
| Half-life | 6-8 hours (normal renal function); prolonged to 12-20 hours in moderate renal impairment. |
| Protein binding | <10% (albumin). |
| Volume of Distribution | 0.8 L/kg (suggests distribution into total body water). |
| Bioavailability | Oral: 98%; IM: 90%. |
| Onset of Action | Oral: 30-60 minutes; IV: 1-2 minutes. |
| Duration of Action | Oral: 6-12 hours; IV: 4-6 hours (based on seizure protection). |
250 mg orally three times daily; maximum 1000 mg/day.
| Dosage form | TABLET |
| Renal impairment | GFR 30-59 mL/min: 250 mg twice daily; GFR 15-29 mL/min: 250 mg once daily; GFR <15 mL/min: 250 mg every other day. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: reduce dose by 75%. |
| Pediatric use | For children 2-12 years: 10 mg/kg/day in 3 divided doses, increasing over 2 weeks to 30 mg/kg/day; maximum 60 mg/kg/day. |
| Geriatric use | Initiate at 125 mg twice daily; titrate slowly; monitor renal function and adjust based on creatinine clearance. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NEURAMATE (NEURAMATE).
| Breastfeeding | NEURAMATE is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.8–1.0. Infant serum levels can reach 10–20% of maternal therapeutic concentrations. Breastfeeding is not recommended due to risk of infant sedation, poor suckling, and potential long-term neurodevelopmental effects. If breastfeeding is essential, monitor infant for excessive drowsiness, feeding problems, and weight gain. |
| Teratogenic Risk | NEURAMATE is classified as FDA Pregnancy Category D. First trimester exposure is associated with a 4-fold increased risk of major congenital malformations, particularly neural tube defects (spina bifida, anencephaly), orofacial clefts, and cardiovascular anomalies. Second and third trimester exposure is linked to decreased IQ scores, autism spectrum disorders, and neurodevelopmental delays in offspring. Neonatal withdrawal syndrome (hyperirritability, feeding difficulties, respiratory distress) may occur with third trimester exposure. |
■ FDA Black Box Warning
Risk of respiratory depression, especially when administered intravenously; risk of dependence and withdrawal; not for use in patients with porphyria.
| Serious Effects |
History of porphyria; severe respiratory insufficiency; hypersensitivity to barbiturates; pregnancy (especially third trimester); breastfeeding; myasthenia gravis; acute or chronic pain.
| Precautions | Respiratory depression; hypotension; paradoxical excitation; risk of abuse and dependence; withdrawal seizures upon abrupt discontinuation; use with caution in hepatic/renal impairment; elderly patients; pregnancy category D. |
Loading safety data…
| Fetal Monitoring | Maternal: Serum NEURAMATE trough levels every 2–4 weeks during pregnancy; liver function tests (AST, ALT, bilirubin) monthly; complete blood count with platelets every 1–2 months; valproate use requires ammonia levels if lethargy or vomiting. Fetal: First trimester ultrasound for neural tube defects (NTD) at 16–18 weeks; fetal echocardiography at 18–22 weeks; serial growth scans every 4–6 weeks in third trimester to detect intrauterine growth restriction (IUGR). Neonatal: Monitor for withdrawal symptoms (Finnegan score) for at least 48 hours post-delivery; check for coagulopathy (vitamin K-dependent factors) due to potential hypoprothrombinemia. |
| Fertility Effects | NEURAMATE may cause menstrual irregularities (anovulatory cycles, amenorrhea) in up to 40% of women of reproductive age, likely due to alterations in gonadotropin-releasing hormone (GnRH) pulsatility. Oligospermia and reduced sperm motility have been reported in men. Reversible upon discontinuation. Polycystic ovary syndrome (PCOS)-like changes may occur with long-term use. |